Deina Walsh - Bone Biologics Chief Officer
| BBLGW Stock | USD 27.80 0.00 0.00% |
Executive
Deina Walsh is Chief Officer of Bone Biologics Corp
| Age | 60 |
| Address | 2 Burlington Woods Drive, Burlington, MA, United States, 01803 |
| Phone | 781 552 4452 |
| Web | https://www.bonebiologics.com |
Deina Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Deina Walsh against Bone Biologics stock is an integral part of due diligence when investing in Bone Biologics. Deina Walsh insider activity provides valuable insight into whether Bone Biologics is net buyers or sellers over its current business cycle. Note, Bone Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bone Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Deina Walsh over six months ago Acquisition by Deina Walsh of 11104 shares of Bone Biologics subject to Rule 16b-3 | ||
Deina Walsh over six months ago Acquisition by Deina Walsh of 12500 shares of Bone Biologics at 3.61 subject to Rule 16b-3 | ||
Deina Walsh over six months ago Bone Biologics exotic insider transaction detected | ||
Deina Walsh over a year ago Purchase by Deina Walsh of 8000 shares of Bone Biologics |
Bone Biologics Management Efficiency
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1903) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.51 in 2024. Return On Capital Employed is likely to climb to -3.08 in 2024. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.Similar Executives
| Found 10 records | EXECUTIVE Age | ||
| Yafit Tehila | Inspira Technologies Oxy | 41 | |
| Eugene III | Biofrontera Warrants | 39 | |
| Jon MBA | Biofrontera Warrants | N/A | |
| Alycia Torres | Biofrontera Warrants | N/A | |
| Daniella YeheskelyHayon | Inspira Technologies Oxy | 47 | |
| Mark Baldyga | Biofrontera Warrants | N/A | |
| Meshira Greenberg | Inspira Technologies Oxy | N/A | |
| Samantha Widdicombe | Biofrontera Warrants | N/A | |
| Adi Nir | Inspira Technologies Oxy | N/A | |
| Daniel JD | Biofrontera Warrants | N/A | |
Management Performance
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 |
Bone Biologics Corp Management Team
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda, CoFounder Board | ||
| Deina Walsh, Chief Officer | ||
| Jeffrey Frelick, CEO President |
Bone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bone Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.